Clinic
VHS Acquisition Subsidiary Number 7 INC
VHS Acquisition Subsidiary Number 7 INC was paid $67.63M by Medicaid between Jan 2018 and Dec 2024, across 342 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoVHS ACQUISITION SUBSIDIARY NUMBER 7 INC
WORCESTER, MA 01608
WORCESTER, MA 01608
33aNPI1538131214assigned 02/06/2006
33bProvider typeEmergency Care Clinic/Center
28Total paid$67.63M
24GClaims1,732,777
24DCodes billed342
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 322,215 | $12.98M | |
| 2019 | 308,818 | $11.18M | |
| 2020 | 233,671 | $7.79M | |
| 2021 | 280,983 | $9.89M | |
| 2022 | 221,665 | $9.67M | |
| 2023 | 213,325 | $8.94M | |
| 2024incomplete | 152,100 | $7.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 75,303 | 66,177 | $11.15M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 54,356 | 49,614 | $7.97M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 41,108 | 36,149 | $6.81M |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.2% | 15,210 | 12,389 | $4.88M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.9% | 67,183 | 22,426 | $4.01M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 11,333 | 10,610 | $1.85M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 10,446 | 9,673 | $1.54M |
| G0378 | Hospital observation service, per hour | 2.3% | 22,228 | 12,126 | $1.53M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 13,054 | 12,048 | $1.45M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.1% | 40,667 | 14,643 | $1.43M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 11,091 | 6,266 | $1.27M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.8% | 1,570 | 1,488 | $1.22M |
330 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.5% | 5,766 | $1.01M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.3% | 2,471 | $900K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 5,322 | $806K |
| 93971 | 1.1% | 3,658 | $771K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 1,332 | $720K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,352 | $625K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 6,519 | $623K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,826 | $622K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,151 | $565K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,297 | $564K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 18,814 | $559K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,103 | $539K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,669 | $515K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,228 | $489K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 4,538 | $478K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,696 | $471K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,892 | $405K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 90,905 | $395K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 38,393 | $394K |
| 97162 | <1% | 8,785 | $373K | |
| 59025 | Fetal non-stress test | <1% | 1,635 | $349K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 781 | $349K |
| 76830 | Ultrasound, transvaginal | <1% | 2,984 | $334K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,893 | $331K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 12,190 | $308K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,647 | $284K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 9,670 | $276K |
| 10060 | <1% | 1,635 | $275K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 8,336 | $270K |
| 76770 | <1% | 2,037 | $257K | |
| 93017 | <1% | 3,808 | $254K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,692 | $218K |
| 93970 | <1% | 851 | $205K | |
| 84484 | <1% | 37,328 | $179K | |
| 76536 | <1% | 1,508 | $169K | |
| 76642 | <1% | 1,498 | $163K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,463 | $155K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 36,583 | $149K |
| 97161 | <1% | 2,625 | $149K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 700 | $132K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,273 | $130K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 327 | $130K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 72,704 | $127K |
| 73630 | <1% | 6,700 | $125K | |
| 77080 | <1% | 2,445 | $125K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 5,006 | $124K |
| ATP08 | <1% | 16,171 | $123K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 695 | $120K |
| 97166 | <1% | 2,635 | $118K | |
| 97116 | <1% | 4,996 | $111K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,345 | $106K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,321 | $105K |
| 83690 | <1% | 23,528 | $103K | |
| ATP14 | <1% | 9,196 | $91K | |
| 81025 | <1% | 16,364 | $89K | |
| 95811 | <1% | 111 | $87K | |
| 12001 | <1% | 443 | $86K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 135 | $83K |
| 73030 | <1% | 4,392 | $78K | |
| 72100 | <1% | 2,764 | $76K | |
| 83880 | <1% | 5,326 | $74K | |
| 82553 | <1% | 13,932 | $74K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,184 | $74K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 44,554 | $70K |
| 0002A | <1% | 2,628 | $69K | |
| 80053 | Comprehensive metabolic panel | <1% | 25,698 | $67K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,255 | $65K |
| 96367 | <1% | 1,093 | $65K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 602 | $64K |
| 83605 | <1% | 12,536 | $64K | |
| 87088 | <1% | 12,880 | $64K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 162 | $64K |
| 73130 | <1% | 4,393 | $63K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 26,205 | $60K |
| 0001A | <1% | 2,914 | $60K | |
| 73560 | <1% | 2,847 | $56K | |
| 90715 | <1% | 2,388 | $55K | |
| 73610 | <1% | 4,216 | $54K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 562 | $52K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,677 | $52K |
| ATP09 | <1% | 6,081 | $49K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,381 | $49K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 331 | $49K |
| 29125 | <1% | 417 | $48K | |
| ATP15 | <1% | 4,967 | $48K | |
| 73562 | <1% | 2,948 | $48K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 103 | $47K |
| 86850 | <1% | 8,287 | $46K | |
| 97035 | <1% | 783 | $44K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 281 | $44K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,484 | $43K |
| 83735 | <1% | 13,493 | $41K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 91 | $40K |
| 73110 | <1% | 2,516 | $40K | |
| 81001 | <1% | 19,539 | $38K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,510 | $37K |
| 93880 | <1% | 420 | $37K | |
| 96415 | <1% | 199 | $36K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 71 | $35K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 27,672 | $35K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,027 | $33K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 450 | $33K |
| 73502 | <1% | 2,211 | $33K | |
| 94729 | <1% | 1,227 | $33K | |
| 12002 | <1% | 153 | $33K | |
| 86900 | <1% | 8,349 | $32K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,270 | $32K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,534 | $31K |
| 84702 | <1% | 2,567 | $30K | |
| 97163 | <1% | 656 | $30K | |
| 70486 | <1% | 631 | $30K | |
| 85027 | <1% | 11,171 | $30K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 16,189 | $30K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,949 | $28K |
| 64483 | <1% | 61 | $28K | |
| 71250 | <1% | 456 | $27K | |
| 85379 | <1% | 4,482 | $27K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 205 | $26K |
| 70496 | <1% | 155 | $26K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 18,340 | $25K |
| 94060 | <1% | 223 | $25K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 104 | $24K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,688 | $23K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,598 | $23K |
| 85730 | <1% | 8,716 | $23K | |
| 87070 | <1% | 4,387 | $22K | |
| 85610 | <1% | 13,143 | $22K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,690 | $22K |
| 12011 | <1% | 110 | $21K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,522 | $20K |
| 87081 | <1% | 4,333 | $20K | |
| 87186 | <1% | 4,090 | $20K | |
| 99219 | <1% | 26 | $19K | |
| 88307 | <1% | 315 | $19K | |
| 87040 | <1% | 3,409 | $18K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,545 | $18K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,313 | $17K |
| 74018 | <1% | 555 | $16K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 19,732 | $16K |
| 82803 | <1% | 1,676 | $16K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,421 | $16K |
| 97113 | <1% | 336 | $16K | |
| 82550 | <1% | 27,913 | $16K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14,770 | $15K |
| 11043 | <1% | 74 | $15K | |
| 86901 | <1% | 8,321 | $14K | |
| 73140 | <1% | 660 | $14K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,407 | $14K |
| ATP16 | <1% | 1,470 | $14K | |
| S9485 | Crisis intervention mental health services, per diem | <1% | 73 | $13K |
| 81003 | <1% | 10,223 | $13K | |
| 81002 | <1% | 6,951 | $13K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,470 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,068 | $13K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,850 | $11K |
| 87210 | <1% | 2,861 | $11K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,843 | $11K |
| 73080 | <1% | 872 | $11K | |
| 95816 | <1% | 45 | $11K | |
| 93923 | <1% | 139 | $10K | |
| 20610 | <1% | 69 | $10K | |
| 43235 | <1% | 26 | $10K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,590 | $10K |
| 80076 | <1% | 13,147 | $9K | |
| 82330 | <1% | 1,911 | $9K | |
| 76870 | <1% | 85 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,833 | $9K |
| 88342 | <1% | 2,096 | $9K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,377 | $9K |
| 71271 | <1% | 200 | $8K | |
| 84703 | <1% | 1,573 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,323 | $8K |
| 94010 | <1% | 129 | $8K | |
| 94726 | <1% | 160 | $8K | |
| 93454 | <1% | 15 | $8K | |
| 90999 | Dialysis (unlisted procedure) | <1% | 127 | $7K |
| 0031A | <1% | 289 | $7K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 71 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 139 | $6K |
| 90686 | <1% | 462 | $6K | |
| 87077 | <1% | 1,700 | $6K | |
| 82565 | <1% | 6,468 | $5K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 2,371 | $5K |
| 82962 | <1% | 39,821 | $5K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,904 | $5K |
| 84100 | <1% | 10,133 | $5K | |
| 82947 | <1% | 5,935 | $5K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 28 | $5K |
| 77065 | Tomosynthesis, mammo | <1% | 119 | $4K |
| 86140 | <1% | 1,907 | $4K | |
| 90674 | <1% | 308 | $4K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 162 | $4K |
| 84520 | <1% | 5,396 | $4K | |
| 94727 | <1% | 66 | $4K | |
| 36430 | <1% | 13 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,724 | $3K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 527 | $3K |
| 71101 | <1% | 490 | $3K | |
| 85651 | <1% | 1,966 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,766 | $3K |
| 73590 | <1% | 417 | $3K | |
| 20552 | <1% | 14 | $3K | |
| 88304 | <1% | 536 | $3K | |
| 82310 | <1% | 4,199 | $3K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 26 | $3K |
| 70498 | <1% | 170 | $3K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,709 | $3K |
| 96376 | <1% | 5,446 | $3K | |
| 83970 | <1% | 640 | $3K | |
| 84295 | <1% | 5,566 | $3K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,764 | $3K |
| 84450 | <1% | 2,142 | $2K | |
| 84460 | <1% | 2,224 | $2K | |
| 74220 | <1% | 25 | $2K | |
| 76942 | <1% | 14 | $2K | |
| 82435 | <1% | 3,863 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,014 | $2K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,562 | $2K |
| 93798 | <1% | 54 | $2K | |
| 82374 | <1% | 3,150 | $2K | |
| 64484 | <1% | 13 | $2K | |
| 80061 | Lipid panel | <1% | 2,780 | $2K |
| 77336 | <1% | 29 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,088 | $2K |
| 84439 | <1% | 415 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,842 | $2K |
| 77002 | <1% | 24 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,148 | $2K |
| 72040 | <1% | 28 | $2K | |
| 77062 | <1% | 12 | $2K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 826 | $2K |
| 29515 | <1% | 12 | $2K | |
| 82247 | <1% | 1,544 | $2K | |
| 84132 | <1% | 2,912 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,625 | $1K |
| 70491 | <1% | 13 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,411 | $1K |
| ATP10 | <1% | 145 | $1K | |
| 74019 | <1% | 122 | $984.67 | |
| 82040 | <1% | 1,272 | $947.07 | |
| 85014 | <1% | 1,478 | $932.35 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 378 | $919.97 |
| 82728 | <1% | 681 | $907.76 | |
| 73090 | <1% | 259 | $844.35 | |
| 87340 | <1% | 685 | $844.00 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 337 | $836.03 |
| 97164 | <1% | 29 | $829.70 | |
| 96411 | <1% | 41 | $801.15 | |
| 87205 | <1% | 325 | $784.00 | |
| 72070 | <1% | 28 | $767.29 | |
| 90714 | <1% | 45 | $766.77 | |
| A9270 | Non-covered item or service | <1% | 22,582 | $765.87 |
| S0028 | Injection, famotidine, 20 mg | <1% | 731 | $765.38 |
| 84075 | <1% | 1,221 | $751.08 | |
| 77066 | Tomosynthesis, mammo | <1% | 93 | $744.60 |
| 82570 | <1% | 221 | $738.48 | |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | <1% | 1,298 | $738.21 |
| 83550 | <1% | 792 | $735.29 | |
| 84112 | <1% | 12 | $700.93 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 934 | $695.46 |
| 84155 | <1% | 1,209 | $628.05 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 115 | $553.38 |
| V2632 | Posterior chamber intraocular lens | <1% | 455 | $547.24 |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 399 | $529.34 |
| ATP03 | <1% | 324 | $529.05 | |
| 96417 | <1% | 78 | $519.81 | |
| C1769 | Guide wire | <1% | 1,732 | $519.63 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,236 | $426.19 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 1,299 | $353.83 |
| 72131 | <1% | 13 | $348.57 | |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | <1% | 166 | $340.98 |
| 73660 | <1% | 12 | $315.32 | |
| ATP07 | <1% | 42 | $305.16 | |
| 87147 | <1% | 110 | $302.45 | |
| J3470 | Injection, hyaluronidase, up to 150 units | <1% | 191 | $297.54 |
| 81015 | <1% | 202 | $233.55 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 34 | $227.32 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 568 | $203.17 |
| 86618 | <1% | 17 | $201.89 | |
| 80164 | <1% | 34 | $195.72 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 140 | $186.78 |
| 87075 | <1% | 44 | $178.40 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 783 | $176.88 |
| 73552 | <1% | 13 | $171.90 | |
| 0011A | <1% | 28 | $169.40 | |
| 84550 | <1% | 154 | $167.23 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 181 | $155.11 |
| 84156 | <1% | 47 | $136.08 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 58 | $127.21 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 232 | $123.35 |
| 86803 | <1% | 61 | $102.04 | |
| 82607 | <1% | 14 | $92.58 | |
| 82746 | <1% | 12 | $91.02 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,292 | $74.91 |
| 73060 | <1% | 28 | $73.55 | |
| 82140 | <1% | 15 | $48.13 | |
| 82010 | <1% | 17 | $43.26 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,412 | $41.01 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,168 | $39.31 |
| 86706 | <1% | 49 | $32.30 | |
| 86704 | <1% | 50 | $23.42 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,328 | $18.46 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 547 | $13.91 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 162 | $7.50 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 476 | $1.99 |
| 99152 | <1% | 12 | $1.78 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 125 | $1.61 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 31 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 523 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 560 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 401 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 28 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 22 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 117 | $0.00 |
| J1270 | Injection, doxercalciferol, 1 mcg | 0% | 125 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 14 | $0.00 |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 0% | 128 | $0.00 |
| 0012A | 0% | 24 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 1,434 | $0.00 |
| 91300 | 0% | 177 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 213 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 116 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 31 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 201 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 71 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 58 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 26 | $0.00 |
| 94664 | 0% | 17 | $0.00 | |
| C8921 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete | 0% | 39 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWHITLOCK JR., JOHN (CFO)
| Provider | Location | Paid |
|---|---|---|
| VHS Acquisition Subsidiary Number 7 INC | Worcester, MA | $353K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.